Search
Aptevo Therapeutics Inc
APVOAdd to Watchlist
4.470USD
+0.020+0.45%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
5.38MMarket Cap
0.00P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Aptevo Therapeutics Inc is 8.00, ranking 167 out of 387 in the Biotechnology & Medical Research industry. The average price target is 420.00, with a high of 420.00 and a low of 420.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
25.500
Target Price
+473.03%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Aptevo Therapeutics Inc
APVO
1
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Aptevo Therapeutics Inc's price target?
Analysts forecast that Aptevo Therapeutics Inc's price target is USD 420.00, with the highest forecast at USD 420.00 and the lowest forecast at USD 420.00.
How have Aptevo Therapeutics IncAPVO's recent earnings per share performed?
The market expectation was USD -6.41, while Aptevo Therapeutics IncAPVO's earnings per share (EPS) for the previous quarter was USD -6.23. EPS for the next quarter is expected at USD -6.01.
What is the analyst rating for Aptevo Therapeutics Inc?
Based on the ratings of Aptevo Therapeutics Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.